KERNS, ROSSM.D. NPI 1023018728 Clinician
Hematology-Oncology · KNOXVILLE, TN
- TENNESSEE CANCER SPECIALISTS PLLC — KNOXVILLE, TN
Group affiliation since 2019
The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.
Year: 2024 · 2023 · 2022 locked column · 2021 locked column · 2020 locked column
Provider overview · all codes · CY2024
The full analytics for this provider
PremiumThe billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.
- Charge, service & beneficiary totals — the disclosed scale, all codes
- Practice profile — focus & reach — top codes by share of services
- Office vs. facility setting mix — place-of-service code split
- Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
- Peer positioning — code breadth — how many codes billed, vs peers
Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.
Notify me at launch → Or see a live example profile →Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Volume locked column | Beneficiary-episodes locked column | Avg charge locked column | Avg Medicare payment locked column |
|---|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | premium | premium | premium | premium |
| J0897 | Injection, denosumab, 1 mg | premium | premium | premium | premium |
| J9299 | Injection, nivolumab, 1 mg | premium | premium | premium | premium |
| J0185 | Injection, aprepitant, 1 mg | premium | premium | premium | premium |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | premium | premium | premium | premium |
| J9271 | Injection, pembrolizumab, 1 mg | premium | premium | premium | premium |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | premium | premium | premium | premium |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | premium | premium | premium | premium |
| J1437 | Injection, ferric derisomaltose, 10 mg | premium | premium | premium | premium |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | premium | premium | premium | premium |
| J9171 | Injection, docetaxel, 1 mg | premium | premium | premium | premium |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | premium | premium | premium | premium |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | premium | premium | premium | premium |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | premium | premium | premium | premium |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | premium | premium | premium | premium |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | premium | premium | premium | premium |
| 80053 | Blood test, comprehensive group of blood chemicals | premium | premium | premium | premium |
| 36415 | Insertion of needle into vein for collection of blood sample | premium | premium | premium | premium |
| J0461 | Injection, atropine sulfate, 0.01 mg | premium | premium | premium | premium |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | premium | premium | premium | premium |
| J2469 | Injection, palonosetron hcl, 25 mcg | premium | premium | premium | premium |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| 96372 | Injection of drug or substance under skin or into muscle | premium | premium | premium | premium |
| 83615 | Lactate dehydrogenase (enzyme) level | premium | premium | premium | premium |
| 82784 | Gammaglobulin (immune system protein) measurement | premium | premium | premium | premium |
| 96375 | Injection of additional new drug or substance into vein | premium | premium | premium | premium |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | premium | premium | premium | premium |
| 82728 | Ferritin (blood protein) level | premium | premium | premium | premium |
| 83550 | Iron binding capacity | premium | premium | premium | premium |
| 83540 | Iron level | premium | premium | premium | premium |
| J3475 | Injection, magnesium sulfate, per 500 mg | premium | premium | premium | premium |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | premium | premium | premium | premium |
| 83521 | Measurement of immunoglobulin light chains | premium | premium | premium | premium |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | premium | premium | premium | premium |
| J9045 | Injection, carboplatin, 50 mg | premium | premium | premium | premium |
| J9190 | Injection, fluorouracil, 500 mg | premium | premium | premium | premium |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | premium | premium | premium | premium |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | premium | premium | premium | premium |
| 99215 | Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | premium | premium | premium | premium |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | premium | premium | premium | premium |
| 83735 | Magnesium level | premium | premium | premium | premium |
| 82607 | Cyanocobalamin (vitamin b-12) level | premium | premium | premium | premium |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | premium | premium | premium | premium |
| 82746 | Folic acid level, serum | premium | premium | premium | premium |
| 84165 | Protein measurement, serum | premium | premium | premium | premium |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | premium | premium | premium | premium |
| 86334 | Immunologic analysis technique on serum (immunofixation) | premium | premium | premium | premium |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | premium | premium | premium | premium |
| 84550 | Uric acid level, blood | premium | premium | premium | premium |
| 96415 | Administration of chemotherapy into vein, each additional hour | premium | premium | premium | premium |
| 82232 | Beta-2 microglobulin (protein) level | premium | premium | premium | premium |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | premium | premium | premium | premium |
| 81002 | Urinalysis, manual test | premium | premium | premium | premium |
| J3489 | Injection, zoledronic acid, 1 mg | premium | premium | premium | premium |
| 85045 | Red blood count, automated test | premium | premium | premium | premium |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | premium | premium | premium | premium |
| J7030 | Infusion, normal saline solution , 1000 cc | premium | premium | premium | premium |
| 82378 | Carcinoembryonic antigen (cea) protein level | premium | premium | premium | premium |
| 84153 | Psa (prostate specific antigen) measurement, total | premium | premium | premium | premium |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | premium | premium | premium | premium |
| 82668 | Erythropoietin (protein) level | premium | premium | premium | premium |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | premium | premium | premium | premium |
| 99205 | New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more | premium | premium | premium | premium |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | premium | premium | premium | premium |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | premium | premium | premium | premium |
| 99195 | Drawing of blood for a medical problem | premium | premium | premium | premium |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | premium | premium | premium | premium |
| 96411 | Administration of additional new drug or substance into vein using push technique | premium | premium | premium | premium |
| 85049 | Platelet count, automated test | premium | premium | premium | premium |
| 85651 | Red blood cell sedimentation rate, to detect inflammation, non-automated | premium | premium | premium | premium |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | premium | premium | premium | premium |
| 83010 | Haptoglobin (serum protein) level | premium | premium | premium | premium |
| 96361 | Infusion into a vein for hydration, each additional hour | premium | premium | premium | premium |
| 96523 | Irrigation of implanted venous access drug delivery device | premium | premium | premium | premium |
| 36591 | Collection of blood sample from implanted device | premium | premium | premium | premium |
| 96374 | Injection of drug or substance into vein | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.